RPCEC00000390已完成2 期
Safety and immunogenicity of the Abdala vaccine in pediatric ages. (COVID-19)
Center for Genetic Engineering and Biotechnology (CIGB), in Havana.0 个研究点目标入组 703 人开始时间: 2021年9月3日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 703
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- N/a: Single Arm Study. Masking: Open. Control Group: Uncontrolled. Assignment: Single Group. Purpose: Prevention
入排标准
- 年龄范围
- 3 years 至 18 years（—）
- 性别
- All
入选标准
- •1) Age between 3 and 18 years at the time of inclusion.
- •2) General physical examination and by appliances without alterations at the time of inclusion.
- •3) Nutritional assessment: weight / height ratio between 10 and 90 percentile (for children between 3 and 9 years of age). Body Mass Index (BMI) for the age between 10 and 90 percentile for adolescents between 10 and 18 years old, according to the cut-off points for the Cuban pediatric population.
- •4) Voluntariness of both parents (or legal guardian) by signing the informed consent, as well as informed consent for adolescents aged =12 years.
排除标准
- •1) History of SARS-CoV-2 infection or with this diagnosis at the time of inclusion in the study.
- •2) Contact or suspect of COVID-19 at the time of inclusion.
- •3) Body temperature = 37ºC at the time of vaccination (vaccination can be deferred up to 48 hours).
- •4) Acute infectious disease in the three days prior to the application of the vaccine.
- •5) Chronic, autoimmune or endocrine-metabolic diseases decompensated at the time of inclusion.
- •6) History of having received a vaccine against SARS-CoV-2 or against other coronaviruses.
- •7) Have received any other vaccine, in the 14 days prior to the administration of each dose.
- •8) Administration of any research product in the last 30 days or that its use is planned during the clinical trial.
- •9) Having been treated in the last 30 days or with any medical condition that requires an immunomodulator (interferon, transfer factor, biomodulin T, thymosin, etc.), steroid (except topical or inhaled) or cytostatic during the study.
- •10) Have received blood, immunoglobulins or blood products in the three months prior to the start of the study.
- •11) Known hypersensitivity to thiomersal and to any of the components of the vaccine under study.
- •12) Tattoos in both deltoid regions that interfere with the injection site safety assessment.
- •13) History or suspicion of alcoholism or drug dependence.
- •14) Positive urine pregnancy test, before the administration of any of the three doses in women with biological capacity to have a pregnancy (history of menarche).
研究者
相似试验
已完成
2 期
Study of HPV Vaccine adverse events and protection in patients with Juvenile Lupus and Juvenile DermatomyositisJuvenile DermatomyositisRBR-9ypbtfCoordenação de Aperfeiçoamento de Pessoal de Nível Superior
已完成
不适用
Phase I Study: safety and immunogenicity of vaccination with XAGE1B long peptides combined with poly-ICLC in patients with pulmonary adenocarcinomalung carcinomanon small cell lung cancer1003866610029107NL-OMON45223eids Universitair Medisch Centrum30
已完成
不适用
Safety and Effectiveness of MVA-BN vaccination against MPXV infection in at-risk individuals in GermanySafety and Effectiveness of MVA-BN vaccination against MPXV infection in at-risk individuals in GermanyB04MonkeypoxDRKS00029638Charité - Universitätsmedizin Berlin15,813
进行中（未招募）
不适用
Evaluation of the immune response and safety of a booster dose of Pfizer's13-valent pneumococcal conjugate vaccine in children primed with 2 dosesof either GSK's 10-valent pneumococcal conjugate vaccine or Pfizer's 13-valent pneumococcal conjugate vaccine in the Slovak RepublicTo induce appropriate protection against pneumococcal disease. Toassess non-inferiority of OPA response for serotype 19A after boosterdose of PCV13 administered between 11-12 months of age in subjectsprimed with 10Pn-PD-DiT vs those primed with PCV13.EUCTR2012-005367-27-SKBIOVOMED
进行中（未招募）
不适用
Evaluation of the immune response and safety of a booster dose of Pfizer’s 13-valent pneumococcal conjugate vaccine in children primed with 3 doses of either GSK’s 10-valent pneumococcal conjugate vaccine or Pfizer’s 13-valent pneumococcal conjugate vaccine in the Czech Republic.To induce appropriate protection against pneumococcal disease. To assess non-inferiority of OPA response for serotype 19A after booster dose of PCV13 administered between 12-15 months of age in subjects primed with 10Pn-PD-DiT vs those primed with PCV13.EUCTR2012-005366-35-CZBIOVOMED